Just caught some interesting movement in the medical device space. STAAR Surgical got FDA approval to expand its EVO lens (technically called an Implantable Collamer Lens or ICL) to patients up to 60 years old, up from the previous 45-year limit. Stock popped 8.4% on the news, which makes sense when you dig into what this actually means.

The approval is backed by solid clinical data from 629 eyes tracked over three years. Safety profile looks really strong - 1.25 safety index with basically no pupillary block or pigment dispersion issues. Anterior subcapsular cataracts showed up in just 0.16% of cases, which is negligible. Surgeons are clearly buying into this tech too. Data from 19 US refractive practices showed EVO ICL being used in over 70% of high myopia cases (minus 8.0 diopters and above).

What's driving this? The refractive correction market is shifting hard. LASIK demand has tanked nearly 40% over the past three years, and patient surveys show 53% of vision correction seekers are now looking at alternatives. That's a massive preference shift. Management estimates there are 24 million myopic adults in the US who could benefit from this ICL approach, with 8 million in that newly approved 46-60 age bracket.

The procedure itself is pretty elegant - minimally invasive, preserves your cornea and natural lens, and it's actually reversible. You get immediate vision improvement while keeping options open for future adjustments as your vision changes. That flexibility matters to a lot of patients.

Stocks down 37.2% over the past six months, so this approval could be a meaningful catalyst. The broader intraocular lens market is growing too - valued around $5.34 billion in 2026 with a projected 4.72% annual growth rate through 2035. Aging population, rising eye disorder prevalence, and better patient awareness of these options are all tailwinds.

One thing to note: the company just appointed interim co-CEOs effective February, so there's some leadership transition happening in the background. But operationally, this age expansion for their flagship ICL product looks like a solid growth driver for the refractive market share going forward.